Journal
PHARMACEUTICS
Volume 12, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics12030256
Keywords
immunogenic cell death; dendritic cell-based vaccination; immunotherapy; cancer treatment
Categories
Funding
- Italian Ministry of Health [GR-2011-02350476]
- Fondazione con il Sud [PDR-0224]
- Agencia Nacional de Promocion Cientifica y Tecnologica [PICT-2017-1755, PICT-2016-0534]
- Regione Campania, POR FESR [CUP B63D18000380007]
Ask authors/readers for more resources
The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not achieve the clinical benefits that were predicted in a number of promising preclinical studies. The current availability of several immune modulatory and targeting approaches opens the way to many potential therapeutic combinations. In particular, the evidence that the immune-related effects that are elicited by immunogenic cell death (ICD)-inducing therapies are strictly associated with DC engagement and activation strongly support the combination of ICD-inducing and DC-based immunotherapies. In this review, we examine the data in recent studies employing tumor cells, killed through ICD induction, in the formulation of anticancer DC-based vaccines. In addition, we discuss the opportunity to combine pharmacologic or physical therapeutic approaches that can promote ICD in vivo with in situ DC vaccination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available